Ballentine Partners’s Quest Diagnostics DGX Stock Holding History

Ballentine Partners’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$648K	Sell	3,058 -1	-0%	-$196	0.01%	484
2026 Q1	$600K	Sell	3,059 -760	-20%	-$148K	0.01%	470
2025 Q4	$663K	Sell	3,819 -91	-2%	-$16.6K	0.01%	416
2025 Q3	$745K	Buy	3,910 +78	+2%	+$13.8K	0.01%	389
2025 Q2	$688K	Buy	3,832 +151	+4%	+$26.2K	0.01%	394
2025 Q1	$623K	Buy	3,681 +2,327	+172%	+$382K	0.01%	381
2024 Q4	$204K	Buy	+1,354	New	+$211K	﹤0.01%	773
2017 Q3	–	Sell	-5,297	Closed	-$571K	–	438
2017 Q2	$571K	Buy	+5,297	New	+$560K	0.04%	182

Other funds holding DGX

Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

AIM

Achmea Investment Management Zeist, Netherlands $4B AUM 31.99% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

JWM

JGP Wealth Management Bend, Oregon $1.11B AUM 35.22% 1-Year Est. Return

Paradiem Covington, Louisiana $464M AUM 45.56% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

GIA

GHP Investment Advisors Denver, Colorado $2.72B AUM 27.58% 1-Year Est. Return

OIAM

OFI Invest Asset Management Paris, France $10B AUM 48.47% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Ballentine Partners's DGX Position: Q2 2026 in Review

Ballentine Partners reduced its Quest Diagnostics (DGX) stake by 0.03% in Q2 2026, selling an estimated $196 and leaving 3,058 shares worth $648K. The position accounts for 0.01% of the portfolio, ranked #484.

Ballentine Partners first reported a position in DGX in Q2 2017 and has held it in 8 quarters since. The position peaked at $745K in Q3 2025. 182 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Ballentine Partners held 3,058 shares of Quest Diagnostics worth $648K as of Q2 2026.
Ballentine Partners sold 1 Quest Diagnostics share in Q2 2026, an estimated $196.
Quest Diagnostics made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #484 holding.
Ballentine Partners first reported a position in Quest Diagnostics in Q2 2017 and has held it in 8 quarters since.
Ballentine Partners's Quest Diagnostics position peaked at $745K in Q3 2025.
182 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.